Get the Stockscreener App
19.61
1.24%
0.24
Structure Therapeutics Inc Adr stock is traded at $19.61, with a volume of 544.30K.
It is up +1.24% in the last 24 hours and up +7.81% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$19.37
Open:
$19.39
24h Volume:
544.30K
Relative Volume:
0.67
Market Cap:
$1.13B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-8.8333
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-2.53%
1M Performance:
+7.81%
6M Performance:
-17.48%
1Y Performance:
-49.91%
1-Day Range:
$19.19
$19.88
1-Week Range:
$18.39
$21.44
52-Week Range:
$13.22
$45.37
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
19.61 | 1.15B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Bergen Record
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform - MarketScreener
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors - The Motley Fool
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity - PR Newswire
Structure Therapeutics’ SWOT analysis: oral GLP-1 stock faces pivotal phase - Investing.com
SEED Therapeutics Named Finalist for 2025 Prix Galien USA 'Best Start-Up” Award - The Manila Times
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Why Is Everyone Talking About UnitedHealth Group Stock? - The Globe and Mail
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - AOL.com
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
High demand expected for new daily weight loss pill - inkl
Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday - Defense World
Structure Therapeutics Reports Q2 2025 Financial Results - TipRanks
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - The Manila Times
The GLP-1 Arms Race: Emerging Innovators and Capital Efficiency in the Obesity Drug Gold Rush - AInvest
Structure Therapeutics Inc ADR (GPCR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Layoff Tracker: Sirona Liquidates TFChem, Merck Will Cut 6,000 Employees - BioSpace
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Eli Lilly & Co (LLY) and Avantor (AVTR) - The Globe and Mail
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Chefs’ Warehouse (NASDAQ:CHEF) Reaches New 52-Week High After Better-Than-Expected Earnings - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17 - Defense World
Brookfield (NYSE:BN) Upgraded at National Bank Financial - Defense World
Camden National (NASDAQ:CAC) Stock Price Down 7.6% Following Weak Earnings - Defense World
Century Lithium (OTC:CYDVF) Shares Down 2.6% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.9% – Here’s What Happened - Defense World
HCM Acquisition (NASDAQ:HCMA) Stock Price Down 3.4% – Here’s Why - Defense World
DeFi Technologies (OTC:DEFTF) Trading 20% Higher – What’s Next? - Defense World
GCM Grosvenor (NASDAQ:GCMGW) Trading Up 1.1% – Should You Buy? - Defense World
Encore Capital Group (NASDAQ:ECPG) & Manhattan Bridge Capital (NASDAQ:LOAN) Critical Review - Defense World
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Obesity Clinical Trials, Companies, Therapeutic Assessment, - openPR.com
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
Private Advisor Group LLC Buys 489 Shares of Quanta Services, Inc. (NYSE:PWR) - Defense World
Analysts Are Bullish on Top Healthcare Stocks: HOYA (HOCPF), Align Tech (ALGN) - The Globe and Mail
Easterly Investment Partners LLC Has $23.78 Million Stock Position in JPMorgan Chase & Co. (NYSE:JPM) - Defense World
Microchip Technology Incorporated (NASDAQ:MCHP) Holdings Decreased by Private Advisor Group LLC - Defense World
Amazon.com, Inc. (NASDAQ:AMZN) Shares Sold by Shilanski & Associates Inc. - Defense World
Viking Therapeutics Posts Wider Q2 Loss - AOL.com
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):